Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-01-23

FDA Approved: KUVAN — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

The FDA approved a supplemental application for KUVAN (sapropterin dihydrochloride) from BioMarin Pharmaceutical, signaling an update to its labeling or indicat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KUVAN (Sapropterin dihydrochloride)

Snippet

SUPPL AP for KUVAN (SAPROPTERIN DIHYDROCHLORIDE)